Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting